Marleen Kok

Only a small subgroup of breast cancer patients seems to benefit from drugs that stimulate the anti-cancer immune response.

Our ambition is three-fold:

1). To develop predictive tests that can be utilized to select breast cancer patients who will benefit from immunotherapy;

2). To explore how we should improve immunotherapy for example by combining immunotherapy with conventional treatments that can be immunostimulatory such as certain chemotherapies, targeted therapies or irradiation;

3). Work towards a better understanding of the anti-breast cancer immune response and the role of various immune cell types in the cancer-immune interaction.